Spironolactone Against Anthracycline-induced Cardiomyopathy

Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy

NCT02053974•TC Erciyes University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Anthracycline Induced Cardiotoxicity

Interventions

Spironolactone

Placebo

Locations

Turkey (Türkiye)

Locations (1)

Erciyes University School of Medicine

Kayseri, Turkey (Türkiye)

Key Dates

Start Date

September 1, 2011

Primary Completion Date

October 1, 2012

Completion Date

October 1, 2012

Last Updated

February 4, 2014

Sponsors

Lead Sponsor

TC Erciyes University

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 4, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions